Palbociclib granted accelerated approval in 2015 for the treatment of ER-positive, HER2-negative advanced BC in association with letrozole [10], and in combination with fulvestrant in patients with ER-positive/HER2-negative advanced BC with disease progression following endocrine therapy [11]. Here, ESR1 is linked to breast cancer.